ZNTL

#3404
Zentalis Pharmaceuticals, Inc. - common stock
3.7 1 USD
-0.01%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
3.71
3.71
Jahresspanne
1.21
6.95
Tagesänderung
-1.33%
Monatliche Änderung
-22.55%
6 month change
+53.94%
Jahresänderung
+119.53%
Vorheriger Schlusskurs
3.7 6
Open
3.7 1
Tief
3.7 1
Hoch
3.7 1
Volumen
40
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Zentalis Pharmaceuticals, Inc. current report, Q2 FY2026
8-K

Zentalis Pharmaceuticals, Inc. current report, Q2 FY2023

Full document

Zentalis Pharmaceuticals, Inc. - Form 8-K Summary

Business Context and Reporting Period

This Current Report on Form 8-K was filed by Zentalis Pharmaceuticals, Inc. on June 5, 2023. The report discloses the presentation of two clinical research posters at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting.

Key Financial Metrics

The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates and does not contain financial statements or performance metrics.

Material Changes and Clinical Updates

  • Item 7.01 (Regulation FD Disclosure): The Company presented a poster titled "A Phase 1/2 Dose Escalation Study of the BCL-2 Inhibitor ZN-d5 and the WEE1 Inhibitor Azenosertib (ZN-c3) in Patients With Acute Myeloid Leukemia (AML)." The poster is furnished as Exhibit 99.1.
  • Item 8.01 (Other Events): The Company presented a poster titled "Correlation of Cyclin E1 Expression and Clinical Outcomes in a Phase 1b Dose-Escalation Study of Azenosertib (ZN-c3), a WEE1 inhibitor, in Combination with Chemotherapy in Patients with Platinum-Resistant or Refractory Epithelial Ovarian, Peritoneal, or Fallopian Tube Cancer." The poster is filed as Exhibit 99.2.

Guidance, Outlook, and Risks

The filing does not contain forward-looking guidance, management commentary on financial outlook, or specific risk factors beyond the standard disclaimer that the poster information is not deemed "filed" for purposes of Section 18 of the Exchange Act. The content is limited to the disclosure of the scientific presentations.

Investor Verification Checklist

  • Review Exhibit 99.1 for detailed data on the ZN-d5 and Azenosertib combination study in Acute Myeloid Leukemia.
  • Review Exhibit 99.2 for detailed data on the Azenosertib and chemotherapy combination study in Ovarian Cancer.
  • Verify the clinical significance of the "Correlation of Cyclin E1 Expression" findings presented at ASCO.
  • Confirm that no financial results were released concurrently with this 8-K filing.

Nachrichten